Zealand Pharma A/S - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ZLDPY Over the counter 2830 www.zealandpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zealand Pharma A/S

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026) - Jun 29th, 2026 9:00 am
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons - Jun 22nd, 2026 2:00 pm
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026) - Jun 22nd, 2026 9:00 am
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Jun 16th, 2026 4:30 pm
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026) - Jun 15th, 2026 9:00 am
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. - Jun 8th, 2026 10:34 am
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026) - Jun 8th, 2026 9:05 am
Zealand Pharma increases its share capital as a result of the exercise of employee warrants - Jun 8th, 2026 9:00 am
Why The Narrative Around Zealand Pharma (CPSE:ZEAL) Is Shifting After Target Resets And Trial Updates - Jun 8th, 2026 12:11 am
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis - Jun 7th, 2026 12:30 pm
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity - Jun 5th, 2026 2:45 pm
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference - Jun 2nd, 2026 9:00 am
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) - Jun 1st, 2026 9:00 am
Zealand Pharma to participate in the Jefferies Global Healthcare Conference - May 27th, 2026 9:00 am
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions - May 27th, 2026 1:00 am
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026) - May 26th, 2026 9:30 am
Resolutions from Zealand Pharma's Extraordinary General Meeting 2026 - May 26th, 2026 8:00 am
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026) - May 14th, 2026 9:00 am
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now? - May 12th, 2026 7:40 am
Zealand Pharma Obesity Trials Shape Future Revenue Potential And Partner Dependence - May 11th, 2026 8:07 pm